Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | NAMPT | P43490 | 7/20 | 0.57 |
| ▸ | LIPE | Q05469 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.48 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MGLL | Q99685 | 1/20 | 0.46 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.46 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16994778 | 0.85 | NAMPT (0.60) | MAPTNAMPTLIPEDGAT1ALDH1A1 | |
| SCHEMBL4672899 | 0.83 | NAMPT (0.61) | NAMPTEPHX2DGAT1ALDH1A1TLR9 | |
| SCHEMBL26742949 | 0.81 | MGLL (0.50) | CNR2LIPEALDH1A1MEN1KMT2A | |
| SCHEMBL4402414 | 0.79 | QDPR (0.59) | MAPTLIPEEPHX2ALDH1A1MEN1 | |
| SCHEMBL4402787 | 0.78 | SLC6A2 (0.44) | CNR2MAPTLIPEALDH1A1 | |
| SCHEMBL23873327 | 0.77 | MEN1 (0.43) | CNR2LIPEMEN1KMT2AMGLL | |
| SCHEMBL15317752 | 0.76 | SLC18A3 (0.44) | MAPTLIPETLR9TLR8TLR7 | |
| SCHEMBL10257746 | 0.76 | CNR2 (1.00) | CNR2MAPTALDH1A1 | |
| SCHEMBL23873286 | 0.76 | MGLL (0.55) | LIPEMGLL | |
| SCHEMBL4402774 | 0.75 | ALDH1A1 (0.49) | CNR2MAPTLIPEALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | ALEXION PHARMACEUTICALS, INC. | 2015-12-10 | — | — | US | disclosed |
| US-9102625-B2 | Nicotinamides as JAK kinase modulators | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-08-11 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150353495-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | CNR2 946/4885MAPT 4633/4885NAMPT 6/4885 |
| US-20120108566-A1 | NICOTINAMIDES AS JAK KINASE MODULATORS | JAK2, JAK1, NADK | CNR2 946/4885MAPT 4633/4885NAMPT 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.